Pharsight

Differin generic

Differin is an acne treatment drug owned by Galderma Labs Lp. It contains adapalene as the active ingredient. Differin was first authorized for market use on 19 June, 2007.

When will Differin generic be available?

The generic version of Differin is expected to be released after 31 May, 2028. This is due to the expiry of the last patent, US7998467, titled 'Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers'.

Differin uses

Differin is primarily used for the topical treatment of acne vulgaris. Its active ingredient, adapalene, contributes to its effectiveness in treating acne.

Differin patent expiration

Differin holds a total of 9 patents and 4 of these have already expired. The last patent, US7998467, will expire on 31 May, 2028, marking the potential release date of Differin generic. Below are the details of the patent:

Differin dosage

Want to ask something?